|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||389.36 g·mol−1|
|3D model (JSmol)|
Suxethonium (trade name: Brevidil-E) is a depolarising muscle relaxant which is presented as a dry powder in an ampoule. This is re-constituted with sterile water prior to use. It is available in Australia as a schedule 4 drug, and the US.
It has some advantages over suxamethonium:
- Less K+
- Possibly less muscle pain after use
- Storage does not require refrigeration
The last advantage was what keeps it in occasional use.
In Australia, it was included in "Resuscitation drugs packs" in hospitals. These packs were sealed boxes containing all the drugs required for an in-hospital resuscitation. They were prepared by the hospital pharmacy and because these were sealed (usually just sticky tape) the drug contents were guaranteed to be there for use in a cardiac arrest. These packs contained ampoules of powdered suxethonium so a relaxant was available to facilitate intubation. Suxamethonium could not be used in these packs because of the requirement for refrigeration. This was certainly an issue in Queensland as it could be quite warm and hospitals wards were in the past generally not air-conditioned.
It can still be used where the storage issue is a concern (e.g. by the military, rural locations, 3rd world countries). The most recent reference to it in Medline is 1976, but it is occasionally mentioned in passing in other journals.
- [dead link]
- "Suxethonium Chloride". Drugs.com.
- Day S (October 1976). "Plasma potassium changes following suxamethonium and suxethonium in normal patients and in patients in renal failure". British Journal of Anaesthesia. 48 (10): 1011–5. doi:10.1093/bja/48.10.1011. PMID 791307.
- Shrestha BM (2003). "Muscle Relaxant in the 21st Century" (PDF). Kathmandu University Medical Journal. 1 (1): 60–65. Archived from the original (PDF) on May 18, 2005.